Flinders Medical Centre

Running trials

• Not yet recruiting

  Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma

  NCT07634289· Phase 2· Source

• Recruiting

  A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

  NCT07623161· Phase 3· Source

• Recruiting

  BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)

  NCT07625644· Phase 3· Source

• Recruiting

  DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

  NCT07544654· Phase 3· Source

• Recruiting

  A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma

  NCT07589634· Phase 2· Source

• Recruiting

  A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions

  NCT07422480· Phase 3· Source

• Recruiting

  A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

  NCT07549412· Phase 3· Source

• Not yet recruiting

  Safety and Efficacy of MiSaver (CB Cells) for Acute Myocardial Infarction, Phase II

  NCT07134712· Phase 2· Source

• Recruiting

  A Clinical Trial to Evaluate NB-4746 in Participants With Amyotrophic Lateral Sclerosis.

  NCT07369076· Phase 1/2· Source

• Recruiting

  Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

  NCT07195695· Phase 3· Source

• Active, not recruiting

  A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

  NCT07170150· Phase 3· Source

• Recruiting

  OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

  NCT07136012· Phase 3· Source

• Not yet recruiting

  Safety of Intrathecal Riluzole in Patients With Amyotrophic Lateral Sclerosis

  NCT07093268· Phase 1· Source

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  NCT07037433· Phase 3· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Source

• Recruiting

  Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

  NCT07177352· Phase 3· Source

• Recruiting

  A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy

  NCT06979375· Phase 2· Source

• Recruiting

  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

  NCT07037459· Phase 3· Source

• Recruiting

  A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  NCT06852222· Phase 3· Source

• Recruiting

  A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

  NCT06892548· Phase 1/2· Source

• Recruiting

  Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

  NCT06731478· Phase 3· Source

• Active, not recruiting

  Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)

  NCT06710132· Phase 1/2· Source

• Recruiting

  A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.

  NCT06284317· Phase 3· Source

• Recruiting

  Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

  NCT06712316· Phase 2/3· Source

• Active, not recruiting

  Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

  NCT06635824· Phase 3· Source

• Recruiting

  CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

  NCT06690775· Phase 2· Source

• Recruiting

  Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)

  NCT06441747· Phase 2· Source

• Active, not recruiting

  A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

  NCT06190951· Phase 2· Source

• Active, not recruiting

  EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

  NCT06531824· Phase 3· Source

• Active, not recruiting

  Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

  NCT06162572· Phase 1/2· Source

• Enrolling by invitation

  Long-term Safety and Tolerability of BHV-7000

  NCT06443463· Phase 2· Source

• Recruiting

  Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

  NCT06252649· Phase 3· Source

• Active, not recruiting

  A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT06425991· Phase 1· Source

• Recruiting

  Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

  NCT06343402· Phase 1· Source

• Active, not recruiting

  Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

  NCT06309966· Phase 2/3· Source

• Active, not recruiting

  A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06254950· Phase 2· Source

• Active, not recruiting

  Magnetic Sentinel Lymph Node Mapping in Upper Gastro-Intestinal Cancer: A Feasibility Clinical Investigation

  NCT05899985· Source

• Recruiting

  A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

  NCT06233461· Phase 2· Source

• Active, not recruiting

  Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)

  NCT06117774· Phase 3· Source

• Recruiting

  A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

  NCT06091254· Phase 3· Source

• Active, not recruiting

  VividWhite Glaucoma Implant (VW-51) Pivotal Study

  NCT06176170· Source

• Active, not recruiting

  Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma

  NCT05864742· Phase 2· Source

• Active, not recruiting

  A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

  NCT05878769· Phase 3· Source

• Active, not recruiting

  Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease

  NCT05701358· Source

• Active, not recruiting

  Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

  NCT05840211· Phase 3· Source

• Recruiting

  Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

  NCT05727904· Phase 3· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

  NCT05503797· Phase 2· Source

• Active, not recruiting

  A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

  NCT05608291· Phase 3· Source

• Recruiting

  International Multicentric Observational Study to Characterize Subpopulations of Patients With Autism Spectrum Disorder

  NCT05590715· Source

• Recruiting

  Guideline Oriented Approach To Lipid Lowering In Asia-Pacific

  NCT05325034· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer7 recruiting
• Coronary artery disease3 recruiting
• ALS (motor neurone disease)2 recruiting
• Colorectal cancer2 recruiting
• Gastric and esophageal cancer2 recruiting
• Heart failure2 recruiting
• Liver and biliary tract cancer2 recruiting
• Myelodysplastic syndromes2 recruiting
• Ovarian cancer2 recruiting
• Acute myeloid leukemia1 recruiting
• Alzheimer disease1 recruiting
• Autism1 recruiting
• Bladder cancer1 recruiting
• Childhood cancers1 recruiting
• Chronic kidney disease1 recruiting
• Crohn's disease1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Epilepsy1 recruiting
• Familial hypercholesterolaemia1 recruiting
• Follicular lymphoma1 recruiting
• Glioblastoma1 recruiting
• High blood pressure1 recruiting
• Melanoma1 recruiting
• Multiple myeloma1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Neuroendocrine tumours1 recruiting
• Obesity1 recruiting
• Thyroid cancer1 recruiting
• Type 2 diabetes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Withdrawn

  Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer

  NCT07353957· Phase 2· Source

• Terminated

  RolloverTreatment With Triumeq for People With ALS Following the Lighthouse II Trial

  NCT06658977· Phase 3· Source

• Terminated

  To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and Bezafibrate

  NCT06488911· Phase 3· Source

• Completed

  A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010

  NCT05867121· Phase 1· Source

• Completed

  IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)

  NCT05989711· Phase 2· Source

• Completed

  Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder

  NCT05512377· Phase 2· Source

• Completed

  A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer

  NCT05505825· Phase 1/2· Source

• Completed

  A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas

  NCT05383352· Phase 1· Source

• Completed

  A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness

  NCT05014672· Phase 2· Source

• Terminated

  Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer

  NCT04958785· Phase 2· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

  NCT05037929· Phase 2· Source

• Completed

  RegoNivo vs Standard of Care Chemotherapy in AGOC

  NCT04879368· Phase 3· Source

• Completed

  DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma

  NCT04334759· Phase 3· Source

• Terminated

  Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

  NCT04093362· Phase 3· Source

• Completed

  Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).

  NCT04472429· Phase 3· Source

• Completed

  Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy

  NCT04471428· Phase 3· Source

• Completed

  Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%

  NCT04435626· Phase 3· Source

• Completed

  A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

  NCT04513925· Phase 3· Source

• Completed

  Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies

  NCT04370704· Phase 1/2· Source

• Completed

  A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

  NCT04172675· Phase 2· Source

• Completed

  TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

  NCT04129502· Phase 3· Source

• Recruiting

  Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)

  NCT03573089· Source

• Terminated

  A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

  NCT04032704· Phase 2· Source

• Completed

  ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB)

  NCT03685448· Phase 2· Source

• Completed

  A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

  NCT03740529· Phase 1/2· Source

• Terminated

  Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia

  NCT03616470· Phase 3· Source

• Completed

  Cardiac Magnetic Resonance GUIDEd Management of Mild-moderate Left Ventricular Systolic Dysfunction.

  NCT01918215· Source

• Completed

  Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer

  NCT00819208· Source